A tech-driven pharmaceutical company based in the U.S. leverages its AI-powered drug development platform, the firm seeks to acquire promising drug candidates and develop them in-house faster and more efficiently than industry norms. The firm is interested in early clinical-stage therapeutic assets, and its typical deal structures include acquisitions and in-licensing. While equity investments are occasionally possible, the firm prefers to take a majority share and does not typically act as a minority investor. The firm is open to opportunities globally.
The firm is interested in traditional therapeutic assets such as small molecules and biologics, with a primary focus on immunology, dermatology, and orphan diseases. Other indications of interest include CNS, cardiovascular, and metabolic diseases. The firm generally avoids cell therapy and oncology. As for development phases, the earliest the firm will consider is within 12 months of IND, with no limitation on how late the asset is in the clinical stage.
The firm does not have specific requirements for a company’s management team, as the firm aims to take over the asset and typically does not act as a minority investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment